

2018  
**IATDMCT**  
Congress

Top science down under  
16–19 September 2018 Brisbane, Australia

## Scientific program

(program is subject to change)


as at 30 August 2018

The red number indicates the paper abstract number

### Sunday 16 September 2018

12:00 – 19:00	<b>Registration desk open</b> Boulevard foyer
13:00 – 15:00	<b>Drugs of use and misuse, Pharmacogenetics and Pharmaco-Justice</b> Pre congress symposium (optional) included in registration
	<b>Room:</b> Boulevard Auditorium
	<b>Chair:</b> Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada
	<b>A laboratory perspective on substance harm reduction - 100</b> Dr Cristiana Stefan, Centre for Addiction and Mental Health, Toronto
	<b>Ethanol, the opioid/drug epidemic and substance abuse involvement in completed suicides - 101</b> Dr Frederic Hellman, Forensic Pathology Department, Ministry of Justice, Pennsylvania, USA
	<b>From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system - 102</b> Dr Yolande Lucire, Medical Practitioner, Australia
	<b>Antiepileptics and hypersensitivity syndrome: Role of ethnicity and epigenetics - 103</b> Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada
14:45 – 15:45	<b>IATDMCT Young Scientist networking afternoon tea</b> Boulevard foyer
16:00 – 17:30	<b>Congress opening session</b>
	<b>Room:</b> Boulevard Auditorium
	<b>Chair:</b> Prof Jennifer Martin, The University of Newcastle, Australia
	<b>Welcome addresses</b> Prof Andrew McLachlan, Co-chair, 2018 Congress Organising Committee
	<b>Presidential welcome address</b> Prof Teun van Gelder, President, IATDMCT
	<b>Plenary presentation</b> <b>Clinical Toxinology - evidence to address the myths - 104</b> Prof Geoff Isbister, The University of Newcastle, Australia
17:30 – 19:00	Welcome cocktail reception Boulevard foyer
Evening	Dinner at leisure







# 2018 IATDMCT Congress

Top science down under

16-19 September 2018 Brisbane, Australia

## Monday 17 September 2018

07:00 – 19:00	Registration desk open Boulevard foyer		
07:30 – 08:30	Morning roundtable sessions (optional, \$20 registration fee)		
	PK/PD of commonly used antibiotics: Do plasma concentrations reflect tissue concentrations? <b>Room:</b> Meeting room B1 <b>Facilitated</b> by Prof Jason Roberts, The University of Queensland, on behalf of the Anti-Infective Drugs Committee	Implementation of TDM in vulnerable patient groups with refractory epilepsy with case examples <b>Room:</b> Meeting room B2 <b>Chairs:</b> Assoc Prof Cecilie Johannessen Landmark and Dr Arton Baftiu, Oslo Metropolitan University and The National Center for Epilepsy, Oslo University Hospital, Norway	
08:45 – 10:15	Plenary presentation <b>Room:</b> Boulevard Auditorium <b>Chairs:</b> Prof Loralie Langman, Chair, Awards Committee and Past President, IATDMCT and Prof Teun van Gelder, President, IATDMCT 2018 IATDMCT C.E. Pippinger Award 2018 IATDMCT Victor Armstrong Young Investigator Award		
10:15 – 10:55	Morning tea, exhibition and poster viewing Boulevard foyer	Supported by 	
11:00 – 13:00	Concurrent session 1		
	<b>Symposium 1: Therapeutic drug monitoring of mycophenolic acid products: Evidence and knowledge gaps, laboratory and clinical experience</b> <b>Room:</b> Meeting room B1 <b>Chair:</b> Prof Teun van Gelder, Erasmus Medical Center, The Netherlands	<b>Symposium 2: Immunogenetics and drugs of use and misuse</b> <b>Room:</b> Meeting room B2 <b>Chair:</b> Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada	<b>Symposium 3: Should we routinely measure unbound drug concentration?</b> <b>Room:</b> Meeting room B3 <b>Chair:</b> Prof Carl Kirkpatrick, Monash University, Australia
	Supported by  <b>The evidence supports dosing of mycophenolic acid (MPA) to a target concentration: Interpreting the literature and research priorities - 105</b> Dr David Metz, The Royal Children's Hospital, Melbourne, Australia <b>Using different analytical methods and matrices to assess the exposure of mycophenolic acid: What is the evidence? - 106</b> Dr Maria Shipkova, Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum-Stuttgart, Germany <b>The interpretation of mycophenolic acid concentrations, considerations to be made - 107</b> Dr Brenda de Winter, Erasmus Medical Center, The Netherlands	<b>Monoclonal antibodies monitoring: Clinical relevant aspects - 109</b> Dr Mario Regazzi, Italian Society of Pharmacokinetics and Biopharmaceutics, (SIFEB), Pavia, Italy <b>PNPLA3 gene polymorphism is associated with predisposition to and severity of Alcoholic Liver Disease (ALD) - 110</b> Dr Devanshi Seth, The University of Sydney; Centenary Institute of Cancer Medicine and Cell Biology, Australia <b>Risk assessment in autoimmune aspect of alcoholic, non-alcoholic and viral hepatitis - 111</b> Dr Paul Haber, The University of Sydney, Drug Health Services, Australia <b>B cell Activating Factor (BAFF) and its Receptor (BAFFR) in kidney transplantation - 112</b> Prof Eberhard Wieland, Medical Center for Diagnostics, Central Institute for	<b>Protein binding and the interpretation of drug concentrations - 114</b> Assoc Prof Matt Doogue, University of Otago, New Zealand <b>TDM and protein binding in critical care – flucloxacillin and phenytoin - 115</b> Dr Paul Chin, University of Otago, New Zealand <b>The relevancy of drug protein binding in pregnancy - 116</b> Dr Rob ter Heine, Radboud University Medical Center, The Netherlands <b>Determining unbound drug concentrations - 117</b> Dr Brett McWhinney, Royal Brisbane and Women's Hospital, Australia <b>Panel discussion</b>

<p><b>Clinical implementation of MPA monitoring, in transplant and beyond - 108</b> Prof Teun van Gelder, Erasmus Medical Center, The Netherlands</p>	<p>Clinical Chemistry and Laboratory, Germany</p> <p><b>Immunotoxicity associated with herbal-induced liver injury - 113</b> Dr Manuela Neuman, University of Toronto Faculty of Medicine, In Vitro Drug Safety and Biotechnology, Canada</p>		
<p>13:00 – 13:55 Lunch with exhibitors</p> <p><b>13:10 Formal poster presentations:</b> Alternative Sampling Strategies, Standards of Practice, TDM in Oncology, Other TDM theme, Analytical methods</p> <p>Boulevard foyer</p>		<p>Supported by</p>  	
<p><b>Shimadzu Scientific Industry workshop</b></p> 	<p><b>Joint meeting for Immunosuppressive Drugs Scientific Committee and the Biomarker Committee</b></p>	<p><b>Clinical Toxicology Committee meeting</b></p>	<p><b>Anti-infective Drugs Committee meeting</b></p>
<p><b>Room:</b> Boulevard Auditorium</p>	<p><b>Room:</b> Meeting room B1</p>	<p><b>Room:</b> Meeting room B2</p>	<p><b>Room:</b> Meeting room B3</p>
<p><b>14:00 – 15:30 Concurrent session 2</b></p>			
<p><b>Symposium 4: Pre-emptive Pharmacogenetic testing</b></p>	<p><b>Contributed papers 1: Anti-infective agents</b></p>	<p><b>Contributed papers 2: TDM in the real world</b></p>	<p><b>Contributed papers 3: Clinical Toxicology</b></p>
<p><b>Room:</b> Boulevard Auditorium</p>	<p><b>Room:</b> Meeting room B1</p>	<p><b>Room:</b> Meeting room B2</p>	<p><b>Room:</b> Meeting room B3</p>
<p><b>Chair:</b> Prof Mark Linder, University of Louisville School of Medicine, USA</p>	<p><b>Chairs:</b> Dr Marieke G.G. Sturkenboom and Dr Indy Sandaradura</p>	<p><b>Chairs:</b> Assoc Prof Matt Doogue and Dr Sophie Stocker</p>	<p><b>Chairs:</b> Dr Nicolas Venisse and Dr Ian Musgrave</p>
<p>Sponsored by</p>  <p><b>Introduction to pre-emptive testing rationale and overview of current approaches for Implementation - 118</b> Prof Mark Linder, University of Louisville School of Medicine, USA</p> <p><b>Implementing Pharmacogenomics in Europe: Design and implementation strategy of the ubiquitous Pharmacogenomics consortium - 119</b> Prof Henk-Jan Guchelaar, Leiden University Medical Center, The Netherlands</p> <p><b>Implementation of a pre-emptive PGX testing strategy in a large US healthcare system - 120</b> Dr Mark Dunnenberger, NorthShore University HealthSystem, USA</p> <p><b>Opportunities and challenges in implementing precision medicine into pharmacy practice - 121</b></p>	<p><b>Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients - 122</b> Assoc Prof Miao Yan, The Second Xiangya Hospital, Central South University, China</p> <p><b>Therapeutic drug monitoring of voriconazole - 123</b> Dr Jane Carland, St Vincent's Hospital, Australia</p> <p><b>Voriconazole for treatment of invasive fungal infection in paediatric patients: Is there need for a more frequent dosing strategy? - 124</b> Dr Jyoti Nehra, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India</p> <p><b>Posaconazole monitoring during real-life in haematological patients: Experience from a tertiary care center - 125</b> Dr Mariadelfina Molinaro, Foundation IRCCS Policlinico San Matteo, Italy</p> <p><b>Retrospective analysis of posaconazole dosing strategy</b></p>	<p><b>Real-world dabigatran concentration monitoring - Christchurch experience - 128</b> Dr Paul Chin, University of Otago, New Zealand</p> <p><b>Lidocaine infusion for pain management in major surgery patients - pharmacokinetic and therapeutic drug monitoring challenges - 129</b> Prof Stein Bergan, Oslo University Hospital, Norway</p> <p><b>A time and motion study of phlebotomists' work - 130</b> Dr Sophie Stocker, St Vincent's Hospital, Australia</p> <p><b>Therapeutic monitoring of antipsychotic efficacy in schizophrenia patients by simultaneous determinations of a panel of biomarkers in plasma - 131</b> Assist Prof HuaLin Cai, Second Xiangya Hospital of Central South University, China</p> <p><b>Barriers overcome: A case study of deploying model-informed precision dosing</b></p>	<p><b>Two concomitant cases of strychnine poisoning - 134</b> Assoc Prof Amanda Jenkins, Umass Memorial Medical Center, USA</p> <p><b>Detection of synthetic opioids using high resolution mass spectrometry: Keeping up with the trends - 135</b> Assoc Prof Kara Lynch, University of California San Francisco, USA</p> <p><b>Designer benzodiazepines pharmacological effects: How to find the information? - 136</b> Dr Souleiman El Balkhi, University Hospital, Limoges, France</p> <p><b>Quantification of metformin in human serum by hydrophilic interaction liquid chromatography - mass spectrometry - 137</b> Dr Ahmed Abdalla, University of South Australia, Australia</p> <p><b>Acute intentional self-poisoning with pesticides: Presentation of two cases and risk factors for severity - 138</b></p>

	Dr Yan-Ting Wang, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China	<b>in a pediatric haematology-oncology population: Single center experience - 126</b> Dr Mariadelfina Molinaro, Foundation IRCCS Policlinico San Matteo, Italy  <b>An international survey on the practice of therapeutic drug monitoring of antifungal drugs - 127</b> Dr Subhosmito Chakraborty, Tata Medical Center, India	<b>across five continents and 50+ sites - 132</b> Dr Robert McLeay, DoseMe, Australia  <b>Evaluation of the pharmacokinetics of psychotropic drugs in HIV-infected patients: Implications for clinical practice - 133</b> Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy	Dr Nicolas Venisse, CIC INSERM 1402 and CHU Poitiers, France  <b>Amodiaquine and the reactive metabolite activate inflammasomes leading to amodiaquine-induced liver injury and agranulocytosis - 139</b> Assoc Prof Ryuji Kato, Osaka University of Pharmaceutical Sciences, Japan
15:30 – 15:55	Afternoon tea, exhibition and poster viewing Boulevard foyer			
16:00 – 17:30	<b>Concurrent session 3</b>			
	<b>Symposium 5: TDM for antiviral agents</b>	<b>Symposium 6: Education in TDM and CT</b>	<b>Symposium 7: Microsampling and dried blood spot analysis</b>	
	<b>Room:</b> Meeting room B1	<b>Room:</b> Meeting room B2	<b>Room:</b> Meeting room B3	
	<b>Chair:</b> Prof Anders Asberg, University of Oslo, Norway	<b>Chair:</b> Dr Staffan Rosenborg, Karolinska University Hospital, Sweden	<b>Chair:</b> Dr Marieke GG Sturkenboom, University Medical Center Groningen, The Netherlands	
	<b>Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus - 140</b> Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy  <b>TDM for valganciclovir in patients with poor renal function after transplantation - 141</b> Prof Teun van Gelder, Erasmus MC, Rotterdam, The Netherlands  <b>Therapeutic drug monitoring for ribavirin in patients with hepatitis - 142</b> Prof Pierre Marquet, Université de Limoges, France	<b>Educating future clinical toxicologists - 143</b> Dr Eric Franssen, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands  <b>Importance of multidisciplinary set-up to enable consistent care and optimised TDM practice through broad education - 144</b> Prof Jennifer Martin, The University of Newcastle, Australia  <b>Education for vancomycin - what works? - 145</b> Dr Jane Carland, St Vincent's Hospital, Australia	<b>Patient Centric Blood Sampling – What is it and where might it be taking us? - 146</b> Dr Neil Spooner, Spooner Bioanalytical Solutions, UK  <b>Dried blood spot; when will it become standard of care? - 147</b> Dr Marieke G.G. Sturkenboom, University Medical Center Groningen, The Netherlands  <b>Microsampling in critically ill patients - 148</b> Dr Suzanne Parker, The University of Queensland, Centre for Clinical Research, Australia	
17:30 – 19:00	Cocktail reception and poster viewing Boulevard foyer			
19:00 – 22:00	<b>Young Scientists Dinner</b> South Beach Social, 30aa Plaza Parklands, South Bank			



# 2018 IATDMCT Congress


Top science down under

16-19 September 2018 Brisbane, Australia

## Tuesday 18 September 2018

06:15	South Bank run		
07:00 – 17:30	Registration desk open Boulevard foyer		
07:30 – 08:30	Morning roundtable sessions (optional, \$20 registration fee)		
	<p><b>Controversy around vancomycin target to achieve optimal therapeutic effect: Trough only or both peak and trough levels, AUC/MIC ratio versus Cmax/MIC ratio: Where is the evidence based practice?</b></p> <p><b>Room:</b> Meeting room B1</p> <p><b>Facilitated by</b> Dr Hundie Tesfaye, Motol University Hospital; Charles University, Prague, Czech Republic</p>	<p><b>Identification and handing of pharmacokinetic interactions of antiepileptic – and psychoactive drugs by TDM and databases</b></p> <p><b>Room:</b> Meeting room B2</p> <p><b>Chairs:</b> Assoc Prof Cecilie Johannessen Landmark, Oslo University Hospital, Norway, Dr Arton Baftiu, Oslo University Hospital, Norway and Dr Tore Haslemo, Diakonhjemmet Trust Hospital, Oslo, Norway</p>	<p><b>Hematocrit and dried blood microsampling: Still an issue?</b></p> <p><b>Room:</b> Meeting room B3</p> <p><b>Chair:</b> Dr Marieke GG Sturkenboom, University Medical Center Groningen, The Netherlands and Prof Christophe Stove, Ghent University, Belgium</p>
08:30 – 09:30	IATDMCT AGM <b>Room:</b> Boulevard Auditorium		
09:30 – 10:15	Plenary presentation		
09:30 – 10:00	<p><b>Room:</b> Boulevard Auditorium</p> <p><b>Chair:</b> Assoc Prof Benedetta Sallustio, The Queen Elizabeth Hospital, Australia</p> <p><b>Translational TDM – integrating evidence into practice</b> Prof Jennifer Martin, The University of Newcastle, Australia</p>		<p>Supported by  SHIMADZU Excellence in Science</p>
10:00 – 10:15	<p><b>Consensus Guidelines 2017 for TDM in Neuropsychopharmacology</b> Prof Werner Steimer, Munich University of Technology, Germany</p>		
10:15 – 10:55	Morning tea, exhibition and poster viewing Boulevard foyer		<p>Supported by  ARK Diagnostics, Inc.</p>
11:00 – 13:00	Concurrent session 4		
	<p><b>Symposium 8: Medicalization and legalization of Cannabis: Short and long-term consequences</b></p> <p><b>Room:</b> Meeting room B1</p> <p><b>Chair:</b> Prof Jennifer Martin, The University of Newcastle, Australia</p>	<p><b>Symposium 9: Dosing decision support tools in special populations: Paediatrics</b></p> <p><b>Room:</b> Meeting room B3</p> <p><b>Chairs:</b> Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA and Dr Hesh Al-Sallami, University of Otago, New Zealand</p>	<p><b>Symposium 10: <i>Staphylococcus aureus</i> blood stream infection mortality is still 30%: Could TDM make a difference?</b></p> <p><b>Room:</b> Meeting room B2</p> <p><b>Chair:</b> Prof Deborah Marriott, St Vincent's Hospital, Australia</p>
	<p><b>Setting the scene – Australia and the world – current regulation status, agriculture regulations and drug development - 201</b> Prof Jennifer Martin, The University of Newcastle, Australia</p> <p><b>Did medical cannabis programs in some US states pave the way for the legalisation of recreational cannabis use? – 202</b></p>	<p><b>Medicine dose-response(s) in children translated into algorithms: population vs individual - 205</b> Dr Hesh Al-Sallami, University of Otago, New Zealand</p> <p><b>Application of decision support tools in hospitals - 206</b> Dr Stefanie Hennig, The University of Queensland, Australia</p>	<p><b>Can we do better? Optimising beta-lactam therapy in <i>S. aureus</i> bacteraemia - 209</b> Prof Deborah Marriott, St Vincent's Hospital, Australia</p> <p><b>Linezolid and telizolid: Is there a role for guided dose optimisation? - 210</b> Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p>



	<p>Prof Wayne Hall, The University of Queensland, Australia</p> <p><b>Issues around taking a plant into clinical practice - 203</b> Dr Peter Galettis, The University of Newcastle, Australia</p> <p><b>Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects - 204</b> Dr Laura Dryburgh, University of Newcastle, Australia</p>	<p><b>Development of dosing support tools for paediatric diseases - 207</b> Prof Catherine Knibbe, University of Leiden, The Netherlands</p> <p><b>Evaluation and integration dosing tools in special populations - 208</b> Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA</p> <p><b>Panel discussion</b></p>	<p><b>Vancomycin: Innovative approaches to getting it right - 211</b> Dr Michael Neely, University of Southern California, USA</p> <p><b>Alternative treatment options for <i>S. aureus</i> infection - 212</b> Dr Natasha Holmes, The Austin Hospital, Australia</p>	
13:00 – 13:55	<p>Lunch with exhibitors</p> <p><b>13:10 Formal poster presentations:</b> Anti-Infective Drugs, Clinical Toxicology/Drugs of Abuse, Immunosuppressive Drugs, Pharmacogenetics, Pharmacometrics/Clinical Pharmacology</p> <p>Boulevard foyer</p> <p style="text-align: right;">Supported by <b>ThermoFisher</b> S C I E N T I F I C</p>			
	<p><b>Waters Corporation Industry workshop:</b></p>  <p><b>Approach for Analysing Infliximab in Serum by LC-MS/MS in TDM</b> Dominic Foley, Senior Scientist, Clinical Scientific Operations, Waters Corporation, Wilmslow, UK</p> <p><b>Transitioning research based TDM assays into a high-through-put clinical service</b> Dr Brett McWhinney, Pathology Queensland, Herston Hospitals Complex, Australia</p>	<p><b>TDM in Oncology Committee meeting</b></p>	<p><b>Toxicology &amp; Environmental Health Committee meeting</b></p>	<p><b>Alternative Sampling Strategies Committee meeting</b></p>
	Room: Boulevard Auditorium	Room: Meeting room B1	Room: Meeting room B2	Room: Meeting room B3
14:00 – 15:30	<b>Concurrent session 5</b>			
	<p><b>Contributed papers 4: Pharmacogenetics and personalised medicine</b></p>	<p><b>Contributed papers 5: Pharmacometrics</b></p>	<p><b>Contributed papers 6: TDM in Oncology</b></p>	
	Room: Meeting room B1	Room: Meeting room B2	Room: Meeting room B3	
	<p><b>Chairs:</b> Dr Daniel Barratt and Prof Satohiro Masuda</p>	<p><b>Chairs:</b> Dr Stephanie Reuter Lange and Dr Brenda de Winter</p>	<p><b>Chairs:</b> Prof Yusuke Tanigawara and Dr Catherine Lucas</p>	
	<p><b>Impact of recipient and donor pharmacogenetics on acute rejection in kidney transplantation - 213</b> Ms Rong Hu, The University of Adelaide, Australia</p> <p><b>Antipsychotic-induced weight gain is associated with FTO gene variants rs9939609 and rs7185735 - 214</b> Prof Werner Steimer, Munich University of Technology, Germany</p> <p><b>Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines - 215</b> Prof Laure Elens, Université Catholique de Louvain, Belgium</p> <p><b>Influence of combined CYP3A4 and CYP3A5 single-nucleotide</b></p>	<p><b>Proposed strategy to refine the phenotyping approach and its implementation to predict drug clearance - 219</b> Mr Jeffrey Adiwidjaja, The University of Sydney, Australia</p> <p><b>A limited sampling strategy for Bayesian estimation of intracellular everolimus exposure in renal transplant recipients - 220</b> Dr Ida Robertsen, University of Oslo, Norway</p> <p><b>A predictive model of ribavirin pharmacokinetics in lung transplant recipients providing guidance for effective dosing - 221</b> Dr Eliza Milliken, St Vincent's Hospital, Australia</p>	<p><b>The cost-effectiveness of Therapeutic Drug Monitoring (TDM) of generic imatinib for the treatment of Chronic Myelogenous Leukemia (CML) - 225</b> Dr Salvatore Salamone, Saladax Biomedical, USA</p> <p><b>Establishment of a national Therapeutic Drug Monitoring (TDM) service for the treatment of challenging childhood cancer patient populations - 226</b> Dr Gareth Veal, Newcastle University, UK</p> <p><b>Association of fludarabine exposure and survival after allogeneic cell transplantation: Retrospectively estimated and prospectively simulated - 227</b> Dr Erik van Maarseveen, University Medical Center Utrecht, The Netherlands</p>	

	<p><b>polymorphisms on tacrolimus exposure in kidney transplant recipients - 216</b> Dr Nadia Ben Fredj, University of Monastir, Tunisia</p> <p><b>Personalized infliximab dosing in inflammatory bowel diseases: Pharmacokinetic-based therapeutic drug monitoring - 217</b> Dr Núria Padullés, Hospital Universitari Bellvitge, Spain</p> <p><b>IL28-B genotyping in HCV infected patients. An old marker with new perspectives - 218</b> Dr Ofelia Noceti, National Center for Liver Transplantation and Liver Diseases, Uruguay</p>	<p><b>Pharmacokinetic modeling and cardiovascular tolerance of intravenous sildenafil in newborns with congenital diaphragmatic hernia - 222</b> Dr Brenda de Winter, Erasmus Medical Center, The Netherlands</p> <p><b>Prediction of CYP3A metabolic phenotype in patients with ziprasidone by blood concentration measurement - 223</b> Dr Yan Zhang, Xi'an Mental Health Center, China</p> <p><b>Evaluation of the predictive performance of population pharmacokinetic models for probabilistic continuous-infusion dosing of meropenem and value of plasma measurements - 224</b> Dr Iris Minichmayr, Medical University Vienna, Austria</p>	<p><b>Paracetamol use prior to HCT conditioning has a significant effect on the within-patient busulfan pharmacokinetics over time - 228</b> Dr Erik van Maarseveen, University Medical Center Utrecht, The Netherlands</p> <p><b>Regorafenib pharmacokinetics and exposure-toxicity relationship in Japanese cancer patients - 229</b> Assoc Prof Masahide Fukudo, Asahikawa Medical University, Japan</p> <p><b>Clinical validation of a DPD functional test in dried saliva sample as predictor of 5-fluorouracil exposure and severe toxicity - 230</b> Dr Marina Antunes, Universidade Feevale, Brazil</p>
15:30 – 15:55	Afternoon tea, exhibition and poster viewing Boulevard foyer		Supported by 
16:00 – 17:30	<b>Concurrent session 6</b>		
	<p><b>Symposium 11: Alternative matrix for the determination of human exposure to environmental pollutants</b></p> <p><b>Room:</b> Meeting room B3</p> <p><b>Chair:</b> David W. Kinniburgh, Alberta Centre for Toxicology, University of Calgary, Canada</p>	<p><b>Symposium 12: Debate – Genotyping of cancer tissue to advise choice of chemotherapy is pharmacologically unsafe</b></p> <p><b>Room:</b> Meeting room B2</p> <p><b>Chair:</b> Prof Euan Walpole, Head of Cancer Services, Brisbane, Australia</p>	<p><b>Symposium 13: The translational science of antidoping – Investigating pure performance</b></p> <p><b>Room:</b> Meeting room B1</p> <p><b>Chairs:</b> Prof Andrew McLachlan, Australia's Antidoping Rule Violation Panel and Dr Naomi Speers, Australian Sports Antidoping Authority, Australia</p>
	<p><b>Breast milk for the estimation of neonatal and lactational exposure to environmental pollutants - 231</b> Prof Jochen Mueller, The University of Queensland, Australia</p> <p><b>Adipose tissue as a site of environmental pollutants accumulation - 232</b> Dr Nicolas Venisse, University Hospital, Poitiers, France</p> <p><b>Pesticide residues analysis in food matrices - 233</b> Dr Souleiman El Balkhi, Limoges University Hospital, France</p>	<p><b>Affirmative:</b> Prof Paul De Souza, University of Western Sydney, Australia Prof Howard Gurney, Macquarie University, Australia Prof Michael Michael, Peter Macallum Cancer Institute, Australia</p> <p><b>Negative:</b> Prof David Thomas, The Kinghorn Cancer Centre, Australia Dr Erik Van Maarseveen, University Medical Center Utrecht, The Netherlands Dr Jessica Ryan, Hunter New England Local Health District and University of Newcastle, Australia</p>	<p><b>Innovations in antidoping –staying ahead of the cheats - 234</b> Daniel Eichner, Sports Medicine Research and Testing Laboratory (SMRTL), USA</p> <p><b>Performance enhancing hormone doping: Biological basis and detection - 235</b> Prof David Handelsman, ANZAC Research Institute and WADA Health Medical Research Committee, Australia</p> <p><b>Innovations and logistics – delivering a modern testing program for the games - 236</b> Dr Lance Brooker, Australian Sports Drug Testing Laboratory, Australia</p>
17:30 – 18:30	IATDMCT Young Scientists committee meeting <b>Room:</b> Meeting room B1		
19:00 – 23:00	<b>Congress dinner</b> Boulevard Room, The Brisbane Convention & Exhibition Centre		



# 2018 IATDMCT Congress

Top science down under


16-19 September 2018 Brisbane, Australia

## Wednesday 19 September 2018

07:00 – 14:30	<b>Registration desk open</b> Boulevard foyer		
07:30 – 08:30	<b>Morning roundtable sessions (optional, \$20 registration fee)</b>		
	<b>Renal replacement therapy modalities and the PK of antimicrobial agents</b>	<b>How do we do better to deal with dosing errors in children?</b>	
	<b>Room:</b> Meeting room B1	<b>Room:</b> Meeting room B2	
	<b>Facilitated</b> by Assoc Prof Darren Roberts on behalf of the Anti-Infective Drugs Committee	<b>Chair:</b> Dr Hesham Al-Sallami, University of Otago, New Zealand	
		<p><b>Understanding the pharmaco-epidemiology of medication errors in children</b> Dr Geert't Jong, Children's Hospital Research Institute of Manitoba, Canada</p> <p><b>The pros and cons of dose scaling and dosing errors in children</b> Assoc Prof Catherine Sherwin, University of Utah School of Medicine, USA</p> <p><b>Roundtable discussion:</b></p> <ul style="list-style-type: none"> <li>Recording and preventing dosing errors in children in your workplace (for clinicians)</li> <li>Current projects around reporting and preventing dosing errors in children (for clinicians and researchers)</li> </ul>	
08:30 – 10:00	<b>Concurrent session 7</b>		
	<b>Contributed papers 7: Immunosuppressants</b>	<b>Contributed papers 8: Clinical Toxicology</b>	<b>Contributed papers 9: Anti-infective drugs</b>
	<b>Room:</b> Meeting room B1	<b>Room:</b> Meeting room B2	<b>Room:</b> Meeting room B3
	<b>Chairs:</b> Prof Satohiro Masuda and Dr Maria Shipkova	<b>Chairs:</b> Dr Nicolas Venisse and Dr Gina Chew	<b>Chairs:</b> Dr Jan Strojil and Dr Catherine Sherwin
	<p><b>High tacrolimus clearance is associated with development of interstitial fibrosis and tubular atrophy in the transplanted kidney - 300</b> Mr Erlend J Egeland, University of Oslo, Norway</p> <p><b>Pharmacokinetic differences between morning and evening administration of tacrolimus in renal transplant recipients – described by a double absorption-phase model - 301</b> Ms Marte Theie Gustavsen, Oslo University Hospital, Norway</p> <p><b>Association of infliximab concentrations with clinical response in psoriasis - 302</b> Dr Núria Padullés, Hospital Universitari Bellvitge, Spain</p> <p><b>Association of pharmacokinetic and pharmacodynamic markers of mycophenolic acid and clinical</b></p>	<p><b>A novel activity-based concept to screen biological matrices for the presence of (synthetic) opioids - 306</b> Dr Annelies Cannaert, Laboratory of Toxicology, Ghent University, Belgium</p> <p><b>Futility of urine salbutamol doping control, demonstrated through pharmacometrics - 307</b> Dr Sven C van Dijkman, Centre for Human Drug Research, The Netherlands</p> <p><b>Routine toxicology analysis including NPS using GC/MS and LC-ion trap MS - 308</b> Dr Gina Chew, Health Sciences Authority, Singapore</p> <p><b>Metabolism of new psychoactive substances studied by metabolomic techniques? A proof of concept study - 309</b> Mr Sascha K Manier, Saarland University, Germany</p>	<p><b>An open-label, multicentre, observational trial to assess teicoplanin levels in critically ill Chinese patients - 312</b> Mrs Wang Xiaoxue, China-Japan Friendship Hospital, China</p> <p><b>Loss of control of HIV viremia with OTC weight-loss drugs: A call for caution? - 313</b> Dr Dario Cattaneo, Luigi Sacco University Hospital, Milan, Italy</p> <p><b>The effectiveness and safety of individualized vancomycin dosing via pharmacokinetic monitoring in critically ill patients - 314</b> Miss Na He, Peking University Third Hospital, China</p> <p><b>Vancomycin – Improving prescribing practices - 315</b> Dr Sophie Stocker, St Vincent's Hospital, Australia</p>



	<p><b>outcomes in cord blood transplant patients - 303</b> Assoc Prof Ikuko Yano, Kobe University Hospital, Japan</p> <p><b>Evaluation of a volumetric absorptive microsampling device for tacrolimus measurement in routine drug monitoring - 304</b> Dr Phillip Morgan, King's College Hospital, UK</p> <p><b>Determination of cyclosporine A following renal transplantation: CMIA or LC-MS/MS? - 305</b> Mrs Wang Xiaoxue, China-Japan Friendship Hospital, China</p>	<p><b>Heavy metals in herbo-mineral formulations in patients undergoing cancer chemotherapy: A tertiary care cancer hospital experience - 310</b> Dr Manjunath Nookala Krishnamurthy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India</p> <p><b>Parabens exposure during pregnancy: Determination in urine of pregnant women from the French EDDS cohort study - 311</b> Dr Nicolas Venisse, CIC INSERM 1402 and CHU Poitiers, France</p>	<p><b>Development of f%T&gt;MIC calculation model and its application in individualized medication optimization of carbopenems in critical care patients - 316</b> Dr Wenqian Chen, China-Japan Friendship Hospital, China</p> <p><b>Beta-lactam concentrations inadequate? Try a gout drug! A case series of probenecid boosting of flucloxacillin 24 hour infusions - 317</b> Ms Cindy Lau, St Vincent's Hospital, Australia</p>
10:00 – 10:25	Morning tea, exhibition and poster viewing Boulevard foyer		
10:30 – 12:30	<b>Concurrent session 8</b>		
	<p><b>Symposium 14: Emerging TDM technologies and obstacles to widespread use</b> Facilitated by ISoP/ACCP Clinical Pharmacometrics Special Interest Group</p> <p><b>Room:</b> Meeting room B1</p> <p><b>Chairs:</b> Dr Michael Neely, University of Southern California, USA and Dr Elizabeth Lakota, Institute for Clinical Pharmacodynamics, USA</p>	<p><b>Symposium 15: Screening for novel psychoactive drugs in clinical and post mortem toxicology</b></p> <p><b>Room:</b> Meeting room B3</p> <p><b>Chair:</b> Dr Eric JF Franssen, OLVG Hospital, Amsterdam, The Netherlands</p>	<p><b>Symposium 16: IATDMCT Young Scientist Symposium</b></p> <p><b>Room:</b> Meeting room B2</p> <p><b>Chairs:</b> Dr Indy Sandaradura, Westmead Hospital, Australia and Prof Laure Elens, Université catholique de Louvain, Belgium</p>
	<p><b>Adaptive Feedback Control (&amp; TDM) need NOT just be based on PK data - 318</b> Dr Gauri Rao, University of North Carolina, USA</p> <p><b>Clinical applications of population pharmacokinetic models of antibiotics - 319</b> Dr Brenda de Winter, Erasmus Medical Center, The Netherlands</p> <p><b>Overcoming obstacles to practical, model-based prescribing - 320</b> Dr Michael Neely, University of Southern California, USA</p> <p><b>Evidence of and barriers to TDM-based precision dosing of oncology drugs - 321</b> Prof Yusuke Tanigawara, Keio University School of Medicine, Tokyo, Japan</p> <p><b>Widespread TDM implementation - You can lead a horse to water... - 322</b> Prof Deborah Marriott, Dr Sophie Stocker and Dr Jane Carland, St Vincent's Hospital, Australia</p>	<p><b>Novel psychoactive substances in the Netherlands and beyond: Challenges for clinical toxicology and pharmacology - 323</b> Dr Tibor Brunt, Amsterdam Institute for Addiction Research, The Netherlands</p> <p><b>How to detect novel psychoactive substances in a clinical setting? - 324</b> Dr Eric JF Franssen, OLVG Hospital, Amsterdam, The Netherlands</p> <p><b>Post mortem toxicology screening in a forensic setting - 325</b> Dr Peter Zweipfenning, KKG, The Hague, The Netherlands and MVZ Dr Stein &amp; Kollegen, Mönchengladbach, Germany</p> <p><b>Interactive panel discussion</b></p>	<p><b>Dried-blood-spots: Challenges and limitations - 326</b> Prof Christophe Stove, Ghent University, Belgium</p> <p><b>Role of LC-MS associated matrix effects and ion suppression in TDM and CT - 327</b> Mr Thomas Bambauer, Saarland University, Germany</p> <p><b>Research since winning award and career advice - 328</b> Dr Dennis Hesselink, Erasmus MC, Rotterdam, The Netherlands</p> <p><b>Monitoring adherence to cardiovascular agents with LCMSMS: A valuable and objective screening tool - 329</b> Dr Erik van Maarseveen, University Medical Center Utrecht, The Netherlands</p>
12:30 – 13:25	Lunch in the trade exhibition and poster viewing Boulevard foyer		

<b>13:30 – 14:30</b>		<b>Plenary presentation and congress close</b>	
		<b>Room:</b> Boulevard Auditorium <b>Chair:</b> Prof Jennifer Martin, The University of Newcastle, Australia  <b>Plenary presentation</b> <b>Tackling antibiotic resistance by targeting virulence not viability – 330</b> Prof Jennifer Martin, Griffith Institute for Drug Discovery (GRIDD), Griffith University, Australia  <b>Congress close</b> Prof Andrew McLachlan, Co-chair, 2018 Congress Organising Committee	
		Supported by  <small>THE SCIENCE OF WHAT'S POSSIBLE.®</small>	
<b>14:30 – 16:30</b>		<b>Post congress workshops (optional) included in registration</b>	
		<b>Bayesian-based Therapeutic Drug Monitoring (TDM) – concepts and applications</b>	<b>Medicalization and legalization of Cannabis: Hot topics</b>
		<b>Room:</b> Meeting room B1	<b>Room:</b> Meeting room B2
		<b>Chairs:</b> Dr Michael Neely, University of Southern California, USA and Prof Pierre Marquet, University of Limoges, France	<b>Chair:</b> Prof Jennifer Martin, The University of Newcastle, Australia
		<b>Part 1: Basic Concepts - 331</b> Dr Elizabeth Lakota, Institute for Clinical Pharmacodynamics, USA  <b>Part 2: Current Applications of Bayesian-based TDM</b>  <b>Bayesian based tacrolimus dosing utilizing patient centered sampling - 332</b> Dr Anders Asberg, Oslo University, Norway  <b>The way to and lessons from &gt;100,000 online Bayesian dose adjustments of immunosuppressants - 333</b> Prof Pierre Marquet, University of Limoges, France  <b>Integrating pharmaco and bacterial dynamics and immunology into optimizing antibiotic therapy - 334</b> Dr Gauri Rao, University of North Carolina, Eshelman School of Pharmacy, USA  <b>Part 3: Moving Forward - 335</b> Dr Michael Neely, University of Southern California, USA	<b>Cannabis and other drug interactions – usefulness of TDM - 336</b> Assoc Prof Jennifer Schneider, The University of Newcastle, Australia  <b>Cannabinoid pharmacology - 337</b> Dr Catherine Lucas, The University of Newcastle, Australia  <b>Synthetic cannabinoids evolution and detection - 338</b> Ms Michelle Williams, The University of Newcastle, Australia  <b>Issues with pharmacometrics/ PKPD modelling and cannabinoids</b> Dr Zheng Liu, The University of Newcastle, Australia